CytomX Therapeutics Inc (NASDAQ:CTMX) traded at $2.65 at close of the session on Friday, May 30 and made an upward move of 5.16% on its previous day’s price.
CytomX Therapeutics Inc has a market cap of $417.49 million and is expected to release its quarterly earnings report in July.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at 19.1M, with a low of 4M and a high of 30M. The median projection represents growth adding up to -23.95% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for current year is expected to hit 98.75M, or -28.49% down from figures reported last year.
On the other hand, looking at the outlook for the CTMX stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy.
Based on estimates by 4 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 1 have rated the CytomX Therapeutics Inc (CTMX) stock as a Hold, while 3 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 43.11% off its SMA20 and 137.44% from its 50-day simple moving average. The RSI (14) is pointing at 75.39 while the volatility over the past week is 6.98% and jumps to 20.22% over the past one month. The beta value is 2.05, while the average true range (ATR) is currently pointing at 0.26. The average price target for the stock over the next 12 months is $5.84, with the estimates having a low of $3.25 and a high of $8. These price ends are -22.64% and -201.89% off the current price level respectively, although investors could be excited at the prospect of a -120.38% if the CTMX share price touches on the median price of $5.84.
